First Aid Shot Therapy, Inc.

First Aid Shot Therapy, Inc. specializes in developing innovative, fast-acting liquid medications designed to alleviate common ailments. Their products provide quick relief through a unique delivery system, catering to health-conscious consumers. First Aid Shot Therapy, Inc.

was founded in 2010 and is headquartered in Burlingame, US. The company focuses on creating effective liquid medications for rapid relief from various health issues. Mary Platerink, one of the co-founders, serves as the CEO. The company has raised a total of USD 24.

00 mn through 3 deals, with the latest being a Series C round on July 10, 2015, led by Johnson & Johnson Innovation and joined by several investors including HealthQuest Capital and Sofinnova Investments. First Aid Shot Therapy, Inc. offers a range of liquid medications aimed at providing quick relief for headaches, nausea, and other common health issues. The products are developed to be easily consumable, ensuring that users receive effective treatment rapidly and conveniently.

The company generates revenue through direct sales of its liquid medication products to consumers. The structure of their sales model allows for straightforward transactions, enhancing customer engagement and encouraging repeat purchases. The focus is on volume sales driven by the accessibility of their product offerings. First Aid Shot Therapy, Inc.

plans to utilize the USD 24. 00 mn raised in their Series C funding to expand their product line and enhance distribution capabilities. They aim to introduce new health-related products designed for fast relief and are exploring expansion into new geographic markets, with specific focus on broader retailer partnerships by 2025. The recent funding will also support marketing initiatives to raise brand awareness in these new regions.